Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 86

The DOI matches its Crossref record.

Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: The BRIGHT study

Beeh, Kai-Michael, Korn, Stephanie, Beier, Jutta, Jadayel, Dalal, Henley, Michelle, D'Andrea, Peter, Banerji, Donald·2014·Respiratory Medicine
DOI 10.1016/j.rmed.2014.01.006
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.rmed.2014.01.006

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 28

  1. O'Donnell, 2006, Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease, Proc Am Thorac Soc, 3, 180, 10.1513/pats.200508-093DO · DOI · Paper page
  2. Bateman, 2013, Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study, Eur Respir J, 42, 1484, 10.1183/09031936.00200212 · DOI
  3. Wedzicha, 2013, Analysis of COPD exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomized, double-blind, parallel-group study, Lancet Respir Med, 1, 199, 10.1016/S2213-2600(13)70052-3 · DOI
  4. Dahl, 2013, Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study, Respir Med, 107, 1558, 10.1016/j.rmed.2013.05.016 · DOI
  5. Balint, 2010, Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone, Int J Chron Obstruct Pulmon Dis, 5, 311
  6. Buhl, 2011, Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD, Eur Respir J, 38, 797, 10.1183/09031936.00191810 · DOI
  7. Dahl, 2010, Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD, Thorax, 65, 473, 10.1136/thx.2009.125435 · DOI
  8. Kornmann, 2011, Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison, Eur Respir J, 37, 273, 10.1183/09031936.00045810 · DOI
  9. Vogelmeier, 2010, Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium, Respir Res, 11, 135, 10.1186/1465-9921-11-135 · DOI
  10. Beeh, 2012, Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial, Int J Chron Obstruct Pulmon Dis, 7, 503, 10.2147/COPD.S32451 · DOI
  11. D'Urzo, 2011, Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial, Respir Res, 12, 156, 10.1186/1465-9921-12-156 · DOI
  12. Kerwin, 2012, Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study, Eur Respir J, 40, 1106, 10.1183/09031936.00040712 · DOI
  13. Barr, 2006, Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis, Thorax, 61, 854, 10.1136/thx.2006.063271 · DOI
  14. Yohannes, 2011, Tiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomes, Respir Care, 56, 477, 10.4187/respcare.00852 · DOI
  15. Cazzola, 2008, Outcomes for COPD pharmacological trials: from lung function to biomarkers, Eur Respir J, 31, 416, 10.1183/09031936.00099306 · DOI
  16. Travers, 2007, Effect of tiotropium bromide on the cardiovascular response to exercise in COPD, Respir Med, 101, 2017, 10.1016/j.rmed.2007.03.008 · DOI
  17. Man, 2004, Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD, Thorax, 59, 471, 10.1136/thx.2003.019620 · DOI
  18. O'Donnell, 2011, Effect of indacaterol on exercise endurance and lung hyperinflation in COPD, Respir Med, 105, 1030, 10.1016/j.rmed.2011.03.014 · DOI · Paper page
  19. Maltais, 2005, Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD, Chest, 128, 1168, 10.1378/chest.128.3.1168 · DOI · Paper page
  20. Thomas, 2013, No room to breathe: the importance of lung hyperinflation in COPD, Prim Care Respir J, 22, 101, 10.4104/pcrj.2013.00025 · DOI · Paper page
  21. O'Donnell, 2004, Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD, Eur Respir J, 23, 832, 10.1183/09031936.04.00116004 · DOI · Paper page
  22. Beeh, 2011, Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD, COPD, 8, 340, 10.3109/15412555.2011.594464 · DOI
  23. Guenette, 2012, Does dynamic hyperinflation contribute to dyspnoea during exercise in patients with COPD?, Eur Respir J, 40, 322, 10.1183/09031936.00157711 · DOI · Paper page
  24. Vogelmeier, 2013, Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study, Lancet Respir Med, 1, 51, 10.1016/S2213-2600(12)70052-8 · DOI
  25. Deschenes, 2008, Locus of symptom limitation and exercise response to bronchodilation in chronic obstructive pulmonary disease, J Cardiopulm Rehabil Prev, 28, 208, 10.1097/01.HCR.0000320074.73846.3b · DOI
  26. Berton, 2010, Effects of tiotropium and formoterol on dynamic hyperinflation and exercise endurance in COPD, Respir Med, 104, 1288, 10.1016/j.rmed.2010.05.017 · DOI · Paper page
  27. Calverley, 2012, Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? the REACT study protocol, Int J Chron Obstruct Pulmon Dis, 7, 375
  28. Tashkin, 2012, Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials, Int J Chron Obstruct Pulmon Dis, 7, 73

Cited by

See all 86

Metadata

Authors
Beeh, K.-M., Korn, S., Beier, J., Jadayel, D., Henley, M., D'Andrea, P., & Banerji, D.
Venue
Respiratory Medicine
Publisher
Elsevier BV
Published
2014-04
Volume
108
Issue
4
Pages
584-592
ISSN
0954-6111
DOI
10.1016/j.rmed.2014.01.006
Cited by
86
References
0
Language
en
Licence
Funders
Novartis Pharma AG, Basel, Switzerland

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: The BRIGHT study. https://app.cochat.ai/papers/10.1016/j.rmed.2014.01.006
The paper
Beeh, K.-M., Korn, S., Beier, J., Jadayel, D., Henley, M., D'Andrea, P., & Banerji, D. (2014). Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: The BRIGHT study. Respiratory Medicine. https://doi.org/10.1016/j.rmed.2014.01.006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.